Results 51 to 60 of about 1,129 (187)

Comparative study to evaluate efficacy and safety of azilsartan and telmisartan in patients with grade I-II essential hypertension [PDF]

, 2017
Background: Objectives of the study was to study the effect of Azilsartan 40mg once daily versus Telmisartan 40mg once daily in patients with Grade I-II essential hypertension.Methods: A prospective study was conducted at MGM Medical college and Hospital
Bhosle, Deepak S., Khan, Sameer, Mubeen, Mohd Faheem, Quazi, Zubair   +3 more
core   +2 more sources

Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension [PDF]

Basic & Clinical Pharmacology & Toxicology, 2017
AbstractAzilsartan (AZL) medoxomil was approved by the United States Food and Drug Administration in 2011 for the treatment of hypertension and has shown promising results both in blood pressure (BP) reduction and in tolerability, but has not yet been taken into practice to the same extent as other angiotensin II receptor blockers (ARBs) that have been
Hjermitslev, Marie Harthøj, Grimm, Daniela, Wehland, Markus, Simonsen, Ulf, Krüger, Marcus   +4 more
openaire   +2 more sources

Azilsartan: Current Evidence and Perspectives in Management of Hypertension

International Journal of Hypertension, Volume 2019, Issue 1, 2019., 2019
Hypertension continues to be global pandemic with huge mortality, morbidity, and financial burden on the health system. Unfortunately, most patients with hypertension would eventually require two or more drugs in combination to achieve their target blood pressure (BP).
Akshyaya Pradhan, Ashish Tiwari, Rishi Sethi, Tomohiro Katsuya   +3 more
wiley   +1 more source

Systematic Review with Network Meta‐Analysis: Comparative Efficacy and Safety of Combination Therapy with Angiotensin II Receptor Blockers and Amlodipine in Asian Hypertensive Patients

International Journal of Hypertension, Volume 2019, Issue 1, 2019., 2019
Background. Hypertension (HTN) is the leading risk factor for cardiovascular mortality globally. The WHO estimates a 60% increase in Asian HTN patients between 2000 and 2025. Numerous studies have compared safety and efficacy between antihypertensive classes, but in‐class comparisons of angiotensin II receptor blockers (ARBs) in combination therapy (CT)
Dae Wook Lee, Mira Jung, Hye Won Wang, Zainah Khan, Philippe Pinton, Tomohiro Katsuya   +5 more
wiley   +1 more source

COMBINATION OF AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE: IS IT POSSIBLE TO FIGHT SYSTEMIC HYPERTENSION AND OBESITY TOGETHER?

Российский кардиологический журнал, 2017
Arterial hypertension (AH) and obesity are the main risk factors of chronic noncommunicable diseases. Adipous tissue is not only a depot for energetic compounds, but is an active endocrine organ synthetizing biologically active substances that facilitate
Yu. A. Vasyuk, E. Yu. Shupenina, E. A. Nesterova, E. I. Golubkova, V. V. Nesvetov   +4 more
doaj   +1 more source

AZILSARTAN AS A POTENT ANTIHYPERTENSIVE DRUG WITH POSSIBLE PLEIOTROPIC CARDIOMETABOLIC EFFECTS: A REVIEW STUDY.

Frontiers in Pharmacology, 2016
Background: Hypertension related cardiovascular (CV) complications could be amplified by the presence of metabolic co-morbidities. Azilsartan medoxomil (AZL-M) is the eighth approved member of angiotensin II receptor blockers (ARBs), a drug class of high
Georgiopoulos Georgios, Vasiliki Katsi, Dimitrios Oikonomou, Georgia Vamvakou, Evangelia Koutli, Aggeliki Laina, Constantinos Tsioufis, Petros Nihoyannopoulos, Petros Nihoyannopoulos, Dimitrios Tousoulis   +9 more
doaj   +1 more source

Uptake and metabolization of four sartan drugs by eight different plants: Targeted and untargeted analyses by HPLC‐drift‐tube‐ion‐mobility quadrupole time‐of‐flight mass spectrometry

ELECTROPHORESIS, Volume 46, Issue 3-4, Page 135-142, February 2025.
Abstract In this study, we investigated the uptake and metabolization of four drugs (plus the associated prodrugs) from the sartan family by eight edible plants. Growing the plants hydroponically in a medium containing the respective drug, more than 40 phases I and II metabolites derived from the four sartan drugs could be tentatively identified.
Laura Zellner, Thomas Schiefer, Markus Himmelsbach, Franz Mlynek, Christian W. Klampfl   +4 more
wiley   +1 more source

Aerobic Exercise and Pharmacological Therapies for Skeletal Myopathy in Heart Failure: Similarities and Differences

Oxidative Medicine and Cellular Longevity, Volume 2016, Issue 1, 2016., 2016
Skeletal myopathy has been identified as a major comorbidity of heart failure (HF) affecting up to 20% of ambulatory patients leading to shortness of breath, early fatigue, and exercise intolerance. Neurohumoral blockade, through the inhibition of renin angiotensin aldosterone system (RAS) and β‐adrenergic receptor blockade (β‐blockers), is a mandatory
Aline V. Bacurau, Telma F. Cunha, Rodrigo W. Souza, Vanessa A. Voltarelli, Daniele Gabriel-Costa, Patricia C. Brum, Matthew C. Zimmerman   +6 more
wiley   +1 more source

State-of-the-art treatment of hypertension: established and new drugs [PDF]

, 2017
The treatment of essential hypertension is based essentially on the prescription of four major classes of antihypertensive drugs, i.e. blockers of the renin-angiotensin system, calcium channel blockers, diuretics and beta-blockers.
Burnier, Michel, Vuignier, Yann, Wuerzner, Gregoire   +2 more
core  

An observational comparative study of different doses of azilsartan and with chlorthalidone combination in moderate hypertension [PDF]

, 2019
Background: High blood pressure (BP) is one of the significant non-communicable diseases that are of high prevalence in our country. Hypertension (HTN) is responsible cause of 57% of stroke and 24% of coronary heart disease deaths in India. Eight classes
Banerjee, Ratul, Chakrabarty, Sourav, Maiti, Tamoghna, Mandal, Sonai, Panda, Amrita   +4 more
core   +2 more sources